Department of Oncology, Odense University Hospital, Denmark; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Radiother Oncol. 2013 Nov;109(2):317-22. doi: 10.1016/j.radonc.2013.06.029. Epub 2013 Jul 25.
To develop a normal tissue complication probability (NTCP) model of radiation-induced biochemical hypothyroidism (HT) after primary radiotherapy for head and neck squamous cell carcinoma (HNSCC) with adjustment for latency and clinical risk factors.
Patients with HNSCC receiving definitive radiotherapy with 66-68Gy without surgery were followed up with serial post-treatment thyrotropin (TSH) assessment. HT was defined as TSH >4.0mU/l. Data were analyzed with both a logistic and a mixture model (correcting for latency) to determine risk factors for HT and develop an NTCP model based on mean thyroid dose (MTD) and thyroid volume.
203 patients were included. Median follow-up: 25.1months. Five-year estimated risk of HT was 25.6%. In the mixture model, the only independent risk factors for HT were thyroid volume (cm(3)) (OR=0.75 [95% CI: 0.64-0.85], p<0.001) and MTD (Gy) (OR=1.12 [95% CI: 1.07-1.20], p<0.001). From the mixture NTCP-model individual dose constraints for a 25% risk of HT were 26, 38, 48 and 61Gy for thyroid volumes of 10, 15, 20 and 25cm(3), respectively.
Comparing the logistic and mixture models demonstrates the importance of latent-time correction in NTCP-modeling. Thyroid dose constraints in treatment planning should be individualized based on thyroid volume.
建立头颈部鳞癌(HNSCC)患者接受原发根治性放疗后发生放射性生化性甲状腺功能减退症(HT)的正常组织并发症概率(NTCP)模型,模型中对潜伏期和临床危险因素进行了调整。
对未接受手术的 HNSCC 患者进行 66-68Gy 根治性放疗,并对其进行了系列的治疗后促甲状腺素(TSH)评估。当 TSH>4.0mU/l 时诊断为 HT。本研究采用逻辑回归和混合模型(对潜伏期进行校正)对 HT 的危险因素进行分析,并基于平均甲状腺剂量(MTD)和甲状腺体积建立 NTCP 模型。
共纳入 203 例患者。中位随访时间:25.1 个月。5 年 HT 估计风险为 25.6%。在混合模型中,HT 的独立危险因素仅为甲状腺体积(cm3)(OR=0.75[95%CI:0.64-0.85],p<0.001)和 MTD(Gy)(OR=1.12[95%CI:1.07-1.20],p<0.001)。根据混合 NTCP 模型,甲状腺体积分别为 10、15、20 和 25cm3 时,发生 HT 风险为 25%的个体剂量限制分别为 26、38、48 和 61Gy。
逻辑回归和混合模型的比较表明潜伏期校正对于 NTCP 模型建立的重要性。在治疗计划中,甲状腺剂量限制应根据甲状腺体积个体化。